Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Inclusion Criteria: * Confirmed diagnosis of hepatocellular carcinoma * Surgical evaluation by a member of the Liver Tumor Program must conclude the patient is not a candidate for resection or ablation * Eastern Cooperative Oncology Group (ECOG) Performance Status Score 0-2 * Able to comprehend and provide written informed consent in accordance with institutional and federal guidelines Exclusion Criteria: * Absolute granulocyte count =\<1,500/ul * Platelet count =\<75,000/ul * Serum creatinine \>= 2.0 mg/dl * Serum bilirubin * \>= 2.0 mg/dl for bilateral treatment or lobar treatment * \>= 3.0 mg/dl for single lesion which could be treated by segmental fusion * History of severe allergy or intolerance to any contrast media, narcotics, sedatives, or atropine * Bleeding, diathesis not correctable by usual forms of therapy * Severe peripheral vascular disease that would preclude catheterization * Portal hypertension with portal venous shunt away from the liver * Evidence of potential delivery greater than 16.5 mCi (30 Gy absorbed dose) of radiation to the lungs on either: 1. first TheraSphere administration; or 2. cumulative delivery of radiation to the lungs \> 30 Gy over multiple treatments * Evidence of any detectable Tc-99m MMA flow to the stomach or duodenum, after application of established angiographic techniques to stop such flow * Significant extrahepatic disease representing an imminent life-threatening outcome * Severe liver dysfunction (Childs' Classification C) or pulmonary insufficiency (requiring continuous oxygen therapy) * Active uncontrolled infection * Significant underlying medical or psychiatric illness * Pregnant women may not participate * Children may not participate